about
Mortality results from a randomized prostate-cancer screening trialCumulative incidence of false-positive results in repeated, multimodal cancer screeningReduced lung-cancer mortality with low-dose computed tomographic screeningLong-term trajectories of self-reported cognitive function in a cohort of older survivors of breast cancer: CALGB 369901 (Alliance).Cognitive impairment in older patients with breast cancer before systemic therapy: is there an interaction between cancer and comorbidity?Using ePrognosis to estimate 2-year all-cause mortality in older women with breast cancer: Cancer and Leukemia Group B (CALGB) 49907 and 369901 (Alliance A151503)Frailty and adherence to adjuvant hormonal therapy in older women with breast cancer: CALGB protocol 369901.Baseline characteristics of participants in the randomized national lung screening trialAssociations among survivorship care plans, experiences of survivorship care, and functioning in older breast cancer survivors: CALGB/Alliance 369901.Prostate cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: mortality results after 13 years of follow-up.Frailty and long-term mortality of older breast cancer patients: CALGB 369901 (Alliance).Personality, coping, and social support as predictors of long-term quality-of-life trajectories in older breast cancer survivors: CALGB protocol 369901 (Alliance).Prostate Cancer Screening in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial: findings from the initial screening round of a randomized trial.Cognitive function and discontinuation of adjuvant hormonal therapy in older breast cancer survivors: CALGB 369901 (Alliance).The Impact of Using Different Reference Populations on Measurement of Breast Cancer-Related Cognitive Impairment Rates.Cumulative incidence of false-positive test results in lung cancer screening: a randomized trial.
P50
Q24601536-9D99999F-8B2F-441E-9755-0DD028A27486Q24642313-D0318863-67EA-480E-985D-0189E92834E8Q28241954-7F85D043-0247-4722-98E8-E16445658E34Q30489606-BB9F2098-60B8-44EA-9F38-D4E6A94ECF0FQ33729085-98251583-0026-4171-8FFA-B7579BBCD82BQ33900866-9F218AA9-7254-4B7A-B247-CDBE555F220DQ33927985-0F42ADD4-54A3-4A29-A32C-C7FC224110FCQ34366877-E35E86E6-7C63-42E9-90E5-B18157AF4779Q35282908-E95358C1-9BEA-4F12-B845-87CA50EC56BBQ35677465-FBD330BF-050A-4831-A1EC-296929C7C381Q38863741-C52C2997-8D9E-40B2-8372-68BC64F2273EQ38951599-8208FCC2-08C6-46DD-B490-03747624C976Q39710858-6EB6DA33-45C6-4BF0-9051-64A6289FF035Q47573348-FA818132-D709-442C-A532-706FF8C449FEQ50422277-1E6D7D9C-0971-45C1-ADFF-D1D8884A5E68Q51144279-F5703C89-321F-4F73-A007-BD748417F97B
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Jonathan Clapp
@ast
Jonathan Clapp
@en
Jonathan Clapp
@es
Jonathan Clapp
@nl
Jonathan Clapp
@sl
type
label
Jonathan Clapp
@ast
Jonathan Clapp
@en
Jonathan Clapp
@es
Jonathan Clapp
@nl
Jonathan Clapp
@sl
prefLabel
Jonathan Clapp
@ast
Jonathan Clapp
@en
Jonathan Clapp
@es
Jonathan Clapp
@nl
Jonathan Clapp
@sl
P106
P21
P31
P496
0000-0002-8058-5808